A 21-week, Multicenter, Open Label Study to Evaluate the Safety and Tolerability Profile of the Combination of a SSRI or SNRI Antidepressive Therapy With Oral Fingolimod in the Treatment of RRMS Patients With Mild to Moderate Depression.

Trial Profile

A 21-week, Multicenter, Open Label Study to Evaluate the Safety and Tolerability Profile of the Combination of a SSRI or SNRI Antidepressive Therapy With Oral Fingolimod in the Treatment of RRMS Patients With Mild to Moderate Depression.

Discontinued
Phase of Trial: Phase IV

Latest Information Update: 23 Jun 2015

At a glance

  • Drugs Fingolimod (Primary) ; Citalopram; Fluoxetine; Venlafaxine
  • Indications Depressive disorders; Multiple sclerosis
  • Focus Adverse reactions
  • Acronyms REGAIN
  • Sponsors Novartis
  • Most Recent Events

    • 23 Jun 2015 Results (no evidence of drug interaction in n=54) presented at the 1st Congress of the European Academy of Neurology.
    • 24 Sep 2014 Status changed from completed to discontinued as reported by ClinicalTrials.gov.
    • 21 Jan 2014 Status changed from active, no longer recruiting to completed accroding to ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top